The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the currently approved SARS-CoV-2 vaccines use the prototype strain-derived spike (S) protein or its receptor-binding domain (RBD) as the vaccine antigen. The emergence of several novel SARS-CoV-2 variants has raised concerns about potential immune escape. In this study, we performed an immunogenicity comparison of prototype strain-derived RBD, S1, and S ectodomain trimer (S-trimer) antigens and evaluated their induction of neutralizing antibodies against three circulating SARS-CoV-2 variants, including B.1.1.7, B.1.351, and B.1.617.1. We found that, at the same antigen dose, the RBD and S-trimer vaccines were more potent than the S1 vaccine in eliciting long-lasting, high-titer broadly neutralizing antibodies in mice. The RBD immune sera remained highly effective against the B.1.1.7, B.1.351, and B.1.617.1 variants despite the corresponding neutralizing titers decreasing by 1.2-, 2.8-, and 3.5-fold relative to that against the wild-type strain. Significantly, the S-trimer immune sera exhibited comparable neutralization potency (less than twofold variation in neutralizing GMTs) towards the prototype strain and all three variants tested. These findings provide valuable information for further development of recombinant protein-based SARS-CoV-2 vaccines and support the continued use of currently approved SARS-CoV-2 vaccines in the regions/countries where variant viruses circulate.
【저자키워드】 COVID-19, neutralizing antibody, Vaccine, Spike protein, Receptor binding domain, SARS-CoV-2 variants, S1, 【초록키워드】 coronavirus disease, viruses, SARS-CoV-2, Coronavirus disease 2019, coronavirus, pandemic, Neutralizing antibodies, B.1.351, Variation, variant, SARS-CoV-2 variant, SARS-CoV-2 vaccines, severe acute respiratory syndrome Coronavirus, virus, immune, SARS-CoV-2 vaccine, Antigen, Protein, Receptor-binding domain, Immune escape, SARS-CoV-2 variants, B.1.1.7, mice, RBD, B.1.617.1, sera, Neutralizing, respiratory, information, Neutralizing titer, dose, Recombinant protein, type strain, Support, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, domain, GMTs, neutralization potency, trimer, wild-type strain, ectodomain, vaccine antigen, MOST, circulating SARS-CoV-2 variants, effective, tested, performed, caused, remained, evaluated, raised, approved, exhibited, less, long-lasting, the RBD, comparable, the vaccine, 【제목키워드】 SARS-CoV-2, recombinant, prototype,